Trial Profile
Phase II Trial of VELCADE (Bortezomib) for Steroid Refractory Acute GVHD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 08 Jun 2011 Primary endpoint added according to ClinicalTrials.gov.
- 08 Jun 2011 Additional lead trial investigator (John Wagner) added as reported by ClinicalTrials.gov.
- 19 Aug 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.